Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:IMR) ) has issued an update.
Imricor Medical Systems reported its fourth-quarter 2025 activities, highlighting a series of clinical and technological milestones that advance real-time MRI-guided cardiac ablation toward broader global adoption. The company announced the world’s first ischemic ventricular tachycardia ablation and the first preclinical pulsed field ablation in the ventricle under real-time MRI guidance, expansion of its VISABL-AFL and VISABL-VT clinical trial programs with new U.S. and European hospital sites, and completed integration of its NorthStar system with Philips scanners, paving the way for site conversions in Europe and the Middle East while continuing integration work with General Electric ahead of a U.S. launch. Commercial momentum included a strengthened board with a former Johnson & Johnson MedTech executive, growing pipeline exceeding 40 sites, new iCMR lab construction and strong physician interest in Saudi Arabia, and heightened public visibility via television coverage. Financially, Imricor recorded operating cash outflows of US$5.2 million and minimal customer receipts in the quarter, reflecting the temporary revenue impact of enrolling hospitals in non-revenue-generating clinical trials, while ending 2025 with US$19.5 million in cash and US$21.3 million in short-term investments, positioning the company to fund its regulatory, clinical, and commercial execution as it seeks to solidify its role in redefining complex arrhythmia treatment without reliance on x-ray.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
More about Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
Imricor Medical Systems, Inc. is a medical technology company pioneering real-time interventional cardiac magnetic resonance (iCMR) procedures, offering MRI-guided cardiac ablations as an alternative to conventional x-ray fluoroscopy. It is currently the only company supplying MRI-compatible consumable devices, including single-use ablation catheters, enabling cardiac ablations to be performed in iCMR labs with the aim of delivering faster, safer and more effective treatments for cardiac arrhythmias through superior MRI imaging of cardiac and vascular structures.
Average Trading Volume: 211,257
Technical Sentiment Signal: Buy
Current Market Cap: A$640.9M
See more data about IMR stock on TipRanks’ Stock Analysis page.